Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors

Oncotarget
Daniela DamianiRenato Fanin

Abstract

CD200, a protein belonging to the immunoglobulin superfamily, has been associated with a poor prognosis in lymphoproliferative disorders and in acute leukemia. We studied the expression of CD200 in a series of 244 patients with diagnosis of acute myeloid leukemia (AML), to evaluate its impact on outcome and its possible association with other known prognostic factors. CD200 was found in 136/244 (56%) patients, in 41 of whom (30%) with high intensity of expression (MFI ≥ 11). CD200 was more frequent in secondary compared to de novo leukemia (p = 0.0006), in CD34 positive cases (p = 0.00001), in Bcl2 overexpressing cases (p = 0.01), in those wild-type Flt3 (p = 0.004) and with favorable or unfavorable compared to intermediate karyotype (p = 0.0003). CD200+ patients have a two-fold lower probability to attain complete remission, both in univariate (p = 0.006) and multivariate (p = 0.04) analysis. The negative impact of CD200 was found also in overall survival (p = 0.02) and was correlated with the intensity of expression of the molecule (p = 0.024). CD200 has an additive negative impact on survival in patients with unfavorable cytogenetic (p = 0.046) and in secondary leukemia (p = 0.05), and is associate with a worsening of outcom...Continue Reading

References

Jan 5, 2001·British Journal of Cancer·C D DalleyA Z Rohatiner
Nov 13, 2001·Clinical and Experimental Immunology·R M GorczynskiJ Lei
Jun 20, 2002·Trends in Immunology·A Neil BarclayMarion H Brown
May 5, 2005·Blood·Martin S TallmanJacob M Rowe
Jan 26, 2007·Leukemia·A TonksR L Darley
Mar 6, 2007·Best Practice & Research. Clinical Haematology·Richard A Larson
Oct 30, 2007·Biochemical and Biophysical Research Communications·Brian T KawasakiWilliam L Farrar
Dec 7, 2007·Biochemical and Biophysical Research Communications·Jérôme MoreauxBernard Klein
Jan 8, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Anke Kretz-RommelKatherine S Bowdish
May 3, 2008·The New England Journal of Medicine·Richard F SchlenkUNKNOWN German-Austrian Acute Myeloid Leukemia Study Group
Sep 9, 2008·Trends in Immunology·Brian T Kawasaki, William L Farrar
Feb 7, 2009·Nature Reviews. Immunology·Dmitry I Gabrilovich, Srinivas Nagaraj
Dec 3, 2009·Breast Cancer Research and Treatment·Reginald M GorczynskiJulia Behnke
Nov 12, 2010·Trends in Immunology·Thomas Condamine, Dmitry I Gabrilovich
Nov 17, 2010·Blood Reviews·Matthew L SmithDavid Grimwade
Nov 26, 2010·Blood·Peter Hokland, Hans Beier Ommen
Dec 18, 2010·Breast Cancer Research and Treatment·Reginald M GorczynskiIsmat Khatri
Dec 20, 2011·American Journal of Clinical Pathology·Daisy AlapatRobert B Lorsbach
Jan 24, 2012·Current Opinion in Immunology·Tomasz P Rygiel, Linde Meyaard
Nov 28, 2012·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ali MemarianMahmood Jeddi-Tehrani
Dec 18, 2012·Blood·Stephen J Forman, Jacob M Rowe
Feb 27, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan K BurnettNigel Russell
Apr 5, 2013·Therapeutic Advances in Hematology·Elihu Estey
Sep 21, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A M MolinaR J Motzer
Nov 13, 2013·The Journal of Clinical Investigation·Xianghong ChenSheng Wei
Jun 1, 2014·Cancer Immunology Research·Kimberly A NoonanIvan Borrello
Oct 17, 2014·American Journal of Hematology·Elihu H Estey
Jan 17, 2015·Current Opinion in Hematology·Ofir Wolach, Richard M Stone
Jan 20, 2015·Journal for Immunotherapy of Cancer·Christopher L MoertelMichael R Olin

❮ Previous
Next ❯

Citations

Apr 26, 2016·Journal of Tissue Engineering and Regenerative Medicine·Yu Qiang SohJodhbir S Mehta
Feb 1, 2017·Molecular Cancer·Kodappully Sivaraman SiveenRamzi M Mohammad
Jun 16, 2017·European Journal of Haematology·Mario TiribelliDaniela Damiani
May 31, 2018·Cancer Biomarkers : Section a of Disease Markers·Asmaa M ZahranHelal F Hetta
Mar 5, 2020·Oncogene·Zhuoyan LiP Brent Ferrell
Mar 22, 2018·Frontiers in Immunology·Marzia DolcinoAntonio Puccetti
Nov 5, 2020·Blood Advances·Jenny M HoJean C Y Wang
Jun 16, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ofrat Beyar-Katz, Saar Gill
Nov 12, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eric K RingGregory K Friedman
Jan 5, 2021·Annals of Surgical Oncology·Yasuko MatsuoYosuke Iwasa
Feb 11, 2021·International Journal of Molecular Sciences·Katarzyna Kotwica-MojzychMariusz Mojzych
Jul 31, 2021·Journal for Immunotherapy of Cancer·Shelley HerbrichMarina Konopleva
Sep 2, 2021·Blood Advances·Paraskevi DiamantiAllison Blair

❮ Previous
Next ❯

Software Mentioned

NCSS

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Cell Adhesion Molecules in the Brain

Cell adhesion molecules found on cell surface help cells bind with other cells or the extracellular matrix to maintain structure and function. Here is the latest research on their role in the brain.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.